Insider Brief
- Renovaro Inc. secured $15 million in additional equity funding, enabling the company to accelerate AI-driven cancer diagnostics and personalized immunotherapy development.
- The company integrates AI and biotechnology to advance early diagnosis, targeted treatments, and drug discovery, leveraging platforms like RenovaroBio for immunotherapy and RenovaroCube for multi-omic diagnostics.
- Renovaro aims to revolutionize precision medicine, using AI-powered solutions to enhance longevity and improve healthcare outcomes.
PRESS RELEASE — Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, has announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
David Weinstein, Chief Executive Officer of Renovaro, commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.”
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group — MZ North America
949–491–8235
[email protected]
www.mzgroup.us
For media inquiries, please contact:
